AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
海角七号
发表于 2024-8-16 13:21:22
193
0
0
The US Food and Drug Administration (FDA) approved a new therapy for the best-selling anti-cancer drug Imfinzi from British pharmaceutical giant AstraZeneca on Thursday (August 15th).
According to media reports on Friday, the FDA has approved Imfinzi as an additional treatment for adult non-small cell lung cancer (NSCLC) patients after surgery.
About one-fifth of all cancer deaths are attributed to lung cancer. Lung cancer is roughly divided into non-small cell lung cancer and small cell lung cancer (SCLC), with approximately 15% of cases classified as small cell lung cancer and the remaining 85% as non-small cell lung cancer.
Imfinzi, as a human monoclonal antibody, helps activate existing anti-cancer immune cells in patients' bodies, more accurately blocking the ability of tumors to evade and suppress the immune system, while enhancing the body's anti-cancer immune response, providing an alternative to chemotherapy.
The data also shows that the drug improved the overall survival rate of a type of lung cancer patient.
The drug was officially approved in the United States in 2017 for the treatment of locally advanced non-small cell lung cancer patients who cannot undergo surgical resection. The cancer cells of these patients are usually unable to be surgically removed, and the disease does not progress after platinum based radiotherapy and chemotherapy, making Imfinzi an alternative immunotherapy.
Earlier this Thursday, AstraZeneca released a press release stating that it has received FDA's priority review for the use of Imfinzi in small cell lung cancer patients with a limited time limit. The FDA's regulatory decision is expected to be officially implemented in the fourth quarter of 2024.
This news pushed the company's stock price to a historic high of £ 132.18 ($170.13) per share during the day, closing at £ 131.66 per share.
Earlier this month, AstraZeneca's market value exceeded £ 200 billion for the first time, firmly ranking as the highest valued listed company in the UK. In US dollar terms, AstraZeneca's market value ranks seventh in Europe.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Li Xiande from Jingke Energy: Maintain strategic patience during the industry's lowest period of downturn. Unprofitable production capacity will be quickly phased out
- Federal Reserve Governor Waller: Stay patient with interest rate cuts, wait for more data!
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Anjin small cell lung cancer treatment drug approved by FDA: can reduce tumor size and prolong lifespan
- AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
-
2024年11月7日,由新华社新闻信息中心、新华社上海分社、新华社品牌工作办公室主办的“品牌·让世界更美好”中外品牌论坛在上海举办。此次论坛,理想汽车荣获“通用ESG企业评价规范”年度最佳品牌奖。理想汽车将 ...
- cool88817
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
何思文表示,“在进博会这个平台上,我们开启的是倾听模式,通过进博会展出各类产品,收集消费者的需求和反馈,进而帮助决定未来进口到中国的产品。过去,汽车行业的许多创新源于美国加州或欧洲。我相信,中国正 ...
- MaxLucky
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
11月5日至10日,第七届中国国际进口博览会(下称“进博会”)在国家会展中心(上海)举办。在进博会期间,平安健康医疗科技有限公司(下称“平安健康”)与美敦力(上海)管理有限公司(下称“美敦力”)达成战 ...
- Hidden2
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏
-
今年上半年业绩表现低迷的百胜中国在第三季度打了个“翻身仗”。11月4日,百胜中国发布三季报显示,今年第三季度,其净利润同比增长22%。而在第一季度、第二季度,该公司净利润增长率分别为-1%、8%,第三季度净 ...
- nihaosifa
- 前天 15:35
- 支持
- 反对
- 回复
- 收藏